MENS Company Profile and Key Details

MENS has shown weak momentum, losing -8.43% over the past week and -94.47% over the past quarter, though year-to-date performance is down -17.47%. Short-term trend indicators are bullishly aligned (SMA20 17.68%, SMA50 -38.92%, SMA200 -91.12%). The stock’s 14-day RSI is 39.41 (weak momentum), while the ATR of 0.57 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -96.39% below its high and over 69.23% above its low. Average 10-day trading volume of 559.87 thousand shares is below the 3-month average of 872.54 thousand, indicating normal recent market interest.

Jyong Biotech Ltd. Ordinary Shares has 76.03 million shares outstanding. The public float is 26.95 million shares, elevated short interest at 0.18% of float. This equals 77.26 thousand shares. The short ratio is 0.33 days. Institutional investors hold 0.36% of the float. Insiders own 62.21%.

Jyong Biotech Ltd. Ordinary Shares (NASDAQ:MENS) closed at $2.42 USD, losing -$0.34 (-12.32%) from the previous close of $2.76. The stock is currently mid-range between its 52-week high and low $1.43 and $67.00. With a market capitalization of about $183.99 million, Jyong Biotech Ltd. Ordinary Shares is classified as a micro-cap and shows higher-than-market volatility (beta ~6.19). Key stats such as the average daily volume over the past year has been around 907.80 thousand shares, volume is running light vs its 52-week average. Headquartered in New Taipei City, None, Jyong Biotech Ltd. Ordinary Shares operates in the Healthcare sector and the Biotechnology industry. Led by CEO Fu-Feng Kuo, the company employs approximately 31 people and listed since June 17, 2025. Jyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases.

Jyong Biotech Ltd. Ordinary Shares last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.24. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Jyong Biotech Ltd. Ordinary Shares stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -17.77%, with price expected at $1.99 by March 10, 2026, within a range of $1.65 to $2.36 3-Month Outlook: Projected fall of -93.39%, reaching $0.16 by May 25, 2026, with a range of $0.00 to $1.41. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by February 24, 2027, within a range of $0.00 to $0.87.

Jyong Biotech Ltd. Ordinary Shares (NASDAQ:MENS) shares are down -17.47% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Jyong Biotech Ltd. Ordinary Shares trading at a premium to the broader market with a P/E of -142.52. Our AI forecast model points to short-term weakness (-17.77% over two weeks), a medium-term fall (-93.39% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Jyong Biotech Ltd. Ordinary Shares trades at a P/E ratio of -142.52, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -7.95 indicating negative book value, which may reflect financial stress. The P/FCF stands at -222454.62, also below market averages.